HomeAI · summaries
Storia in 2 fonti
‘Seeing the evolution’: As branded patent cliff looms, biosimilar experts size up US hurdles, opportunities ahead
The tables have turned for the U.S. biosimilars market. | With more than a decade passed since the first FDA biosim approval, strong launches of biologic copies to AbbVie’s Humira, J&J’s Stelara and Regeneron/Bayer’s Eylea are shifting a narrative once focused on lagging uptake of the category in The States.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
‘Seeing the evolution’: As branded patent cliff looms, biosimilar experts size up US hurdles, opportunities ahead
The tables have turned for the U.S. biosimilars market. | With more than a decade passed since the first FDA biosim approval, strong launches of biologic copies to AbbVie’s…
- ·
fiercebiotech.com
FDA halts release of new drug rejection letters while working to formalize policy
The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has learned, following a citizen’s petition from an…